AstraZeneca to test Alzheimer's Drug for Adult ADHD

AstraZeneca and Targacept will begin Phase II trials to see the effectiveness of an experimental drug in adults with ADHD.

Tuesday June 10th - 1:42pm

A drug currently being developed by AstraZeneca and the biotech firm Targacept for the treatment of Alzheimer's and cognitive dysfunction in Schizophrenia has shown "compelling attentional effects."

Because of these findings, the two companies will soon begin Phase II trials of the medication for adults with ADHD. The researchers hope to find the efficacy of two different dose strengths of the drug. The study will incorporate a crossover double-blind procedure in which each participant will get a placebo and each dosage of the medication at different times during the study.

Copyright © 1998 - 2013 New Hope Media LLC. All rights reserved. Your use of this site is governed by our Terms of Service and Privacy Policy.
ADDitude does not provide medical advice, diagnosis, or treatment. The material on this web site is provided for educational purposes only. See additional information.
New Hope Media, 39 W. 37th Street, 15th Floor, New York, NY 10018